Moreover, due to the neuron-specific action of MCH on metabolic processes such as peripheral lipid deposition, induction of glucose intolerance, or feeding, the use of novel technologies that target specific neuron populations in the brain could provide new avenues in the development of MCH based therapies for treating metabolic diseases. This evidence concerns the gene PMCH and Other metabolic disease.